Rheumatoid arthritis: Current and future trends

Nature Reviews Drug Discovery

Volumn 15, Issue 5, 2016, Pages 305-306

  Chaudhari, Kritika ^a   Rizvi, Salman ^b   Syed, Basharut A ^c  

^a Biomed Insights   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c FirstWord Pharma   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALX 0061; BARICITINIB; CERTOLIZUMAB PEGOL; CLAZAKIZUMAB; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FILGOTINIB; GOLIMUMAB; INFLIXIMAB; MAVRILIMUMAB; METHOTREXATE; PLACEBO; RITUXIMAB; SARILUMAB; SIRUKUMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UPADACITINIB; ANTIRHEUMATIC AGENT;

DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; ARTHRITIS, RHEUMATOID;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 84963502518     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.21     Document Type: Short Survey

References (1)

1. World Health Organization. Chronic rheumatic conditions [online]: http://www.who.int/chp/topics/rheumatic/en/